LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Strona główna・Stock List・Guardant Health Inc

Guardant Health Inc

Closed

SectorHealthcare

129.56 -2.45

Buy Sell

Overview

Share price change

24h

Current

Min

127.8

Max

133.3

Key metrics
By Trading Economics
Income	16M -112M
Sales	20M 302M
EPS	-0.45
Profit margin	-37.152
Employees	2,490
EBITDA	18M -101M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	-1.12% downside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	3.7B 16B
Previous open	132.01
Previous close	129.56

News Sentiment

By Acuity

50%

161 / 344 Ranking in Healthcare

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 maj 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 maj 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 maj 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 maj 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 maj 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 maj 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 maj 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 maj 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 maj 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 maj 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 maj 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 maj 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 maj 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 maj 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 maj 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 maj 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 maj 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 maj 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 maj 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

-1.12% downside

12 Months Forecast

Average 131.73 USD -1.12%

High 160 USD

Low 95 USD

Based on 16 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Guardant Health Inc - Dist in the past 3 months.

Sentiment

By Acuity

161 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.